Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.66 |
| ▸ | CES1 | P23141 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703169 | 1.00 | CES2 (0.66) | CES2CES1GSK3BTP53ALDH1A1 | |
| SCHEMBL1986403 | 0.86 | CES2 (0.70) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL30512072 | 0.84 | CES2 (0.68) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL17347345 | 0.84 | GSK3B (0.52) | CES2CES1GSK3BTP53ALDH1A1 | |
| SCHEMBL312393 | 0.84 | CES2 (0.68) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL16236714 | 0.84 | CES2 (0.48) | CES2CES1GSK3BTP53ALDH1A1 | |
| SCHEMBL29803072 | 0.84 | KCNH2 (0.62) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL21643228 | 0.84 | KCNH2 (0.62) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL10792180 | 0.83 | TSHR (0.67) | CES2CES1TP53ALDH1A1TSHR | |
| SCHEMBL602616 | 0.83 | CES2 (0.66) | CES2CES1TP53ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 870 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880786-A | Synthesis method and antioxidant application of camphene aldehyde thiazole hydrazone derivative | 江西农业大学 | 2022-01-04 | — | — | CN | claimed |
| CN-108676016-B | Synthetic method of myrtenal aldehyde imidazo [2,1-b ] [1,3,4] thiadiazole compound | 广西大学 | 2021-02-26 | — | — | CN | claimed |
| CN-109456280-B | 4-phenylthiazole-2-amine derivative containing urea structure and preparation method and application thereof | 锦州医科大学 | 2020-11-10 | — | — | CN | claimed |
| CN-108840827-A | The method of the quinoxaline that one-step synthesis method dinitro replaces or derivatives thereof | 同济大学 | 2018-11-20 | — | — | CN | claimed |
| US-9870909-B2 | Compositions and methods for mass spectometry | MSTM, LLC | 2018-01-16 | — | — | US | claimed |
| US-20140235863-A1 | SUBSTITUTED 4-ARYLTHIAZOLES AND PROCESS OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-21 | — | — | US | claimed |
| WO-2012164572-A1 | SUBSTITUTED 4-ARYLTHIAZOLES AND PROCESS OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-12-06 | — | — | WO | claimed |
| CN-1765503-A | Quarternary ammonium salt of quinine compound, its preparation method and use | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2006-05-03 | — | — | CN | claimed |
| CN-117285470-B | Electropolymerizable ionic liquid, polymer, battery pole piece and preparation method thereof | TIANMU LAKE INSTITUTE OF ADVANCED ENERGY STORAGE TECHNOLOGIES Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-11-06 | — | — | US | disclosed |
| EP-3609888-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12384813-B2 | Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates | MIRECA MEDICINES GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| US-4265807-A | TO INCREASE ITS OXIDATION RESISTANCE | HERCULES INCORPORATED (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0019796-A1 | Propionic acid esters, preparation of these compounds, herbicides containing these compounds as active substances, and the use of such compounds and agents for combating weeds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-12-10 | — | — | EP | disclosed |
| US-4212865-A | BACTERICIDES | RIKER LABORATORIES, INC. (US) | 1980-07-15 | — | — | US | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
| EP-0003640-A2 | Antisecretory guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-08-22 | — | — | EP | disclosed |
| US-4143148-A | ANTI-ULCER THIAZOLINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384813-B2 | Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates | PRKG1, PRKG2, PRKAG3 | CES2 3824/4885CES1 4131/4885GSK3B 165/4885 |
| US-20140235863-A1 | SUBSTITUTED 4-ARYLTHIAZOLES AND PROCESS OF PREPARATION THEREOF | TST, NQO1, FNTB | CES2 781/4885CES1 832/4885GSK3B 3349/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | CES2 1489/4885CES1 951/4885GSK3B 2016/4885 |
| US-20250340560-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | CES2 3959/4885CES1 2036/4885GSK3B 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.